Last reviewed · How we verify
DARVADSTROCEL
At a glance
| Generic name | DARVADSTROCEL |
|---|---|
| Modality | Cell therapy |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2018 |
Approved indications
Common side effects
Key clinical trials
- A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula (PHASE4)
- A Survey of Darvadstrocel in People With Crohn's Disease
- A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease (PHASE3)
- A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer
- Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula (PHASE3)
- Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease (PHASE3)
- Darvadstrocel for Crohn's Fistula in the Realworld
- National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |